NASDAQ:ACRS - Aclaris Therapeutics Stock Price, Forecast & News

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Aclaris Therapeutics Inc (NASDAQ:ACRS) issued its earnings results on Thursday, November, 7th. The biotechnology company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($0.54) by $0.80. The biotechnology company earned $0.98 million during the quarter, compared to analyst estimates of $5.87 million. Aclaris Therapeutics had a negative net margin of 1,165.39% and a negative return on equity of 83.22%. View Aclaris Therapeutics' Earnings History.

Aclaris Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Aclaris Therapeutics.

5 analysts have issued 1-year price targets for Aclaris Therapeutics' stock. Their forecasts range from $5.00 to $13.00. On average, they anticipate Aclaris Therapeutics' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 529.4% from the stock's current price. View Analyst Price Targets for Aclaris Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aclaris Therapeutics.

News articles about ACRS stock have been trending positive on Tuesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aclaris Therapeutics earned a daily sentiment score of 3.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Aclaris Therapeutics.

Aclaris Therapeutics saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 3,670,000 shares, a drop of 5.9% from the December 15th total of 3,900,000 shares. Based on an average daily volume of 951,100 shares, the days-to-cover ratio is currently 3.9 days. Approximately 11.0% of the shares of the stock are short sold. View Aclaris Therapeutics' Current Options Chain.

Some companies that are related to Aclaris Therapeutics include Wave Life Sciences (WVE), BIOFRONTERA AG/ADR (BFRA), Kala Pharmaceuticals (KALA), Neptune Wellness Solutions (NEPT), Avadel Pharmaceuticals (AVDL), Sol Gel Technologies (SLGL), Evofem Biosciences (EVFM), Concert Pharmaceuticals (CNCE), MEI Pharma (MEIP), VBI Vaccines (VBIV), Seres Therapeutics (MCRB), Theratechnologies (THERF), Ocular Therapeutix (OCUL), Athersys (ATHX) and Theratechnologies (THTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Nabriva Therapeutics (NBRV), Progenics Pharmaceuticals (PGNX), Viking Therapeutics (VKTX), Zynerba Pharmaceuticals (ZYNE), Abeona Therapeutics (ABEO) and Exelixis (EXEL).

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACRS stock can currently be purchased for approximately $1.43.

Aclaris Therapeutics has a market capitalization of $59.18 million and generates $10.09 million in revenue each year. The biotechnology company earns $-132,740,000.00 in net income (profit) each year or ($4.03) on an earnings per share basis. Aclaris Therapeutics employs 169 workers across the globe.View Additional Information About Aclaris Therapeutics.

The official website for Aclaris Therapeutics is http://www.aclaristx.com/.

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]